CN105130888A - 炔基吡啶类脯氨酰羟化酶抑制剂、其制备方法和医药用途 - Google Patents

炔基吡啶类脯氨酰羟化酶抑制剂、其制备方法和医药用途 Download PDF

Info

Publication number
CN105130888A
CN105130888A CN201510648342.9A CN201510648342A CN105130888A CN 105130888 A CN105130888 A CN 105130888A CN 201510648342 A CN201510648342 A CN 201510648342A CN 105130888 A CN105130888 A CN 105130888A
Authority
CN
China
Prior art keywords
compound
propyne
preparation
pharmaceutically acceptable
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201510648342.9A
Other languages
English (en)
Chinese (zh)
Inventor
张晓进
尤启冬
雷永华
胡天寒
吴杏森
孙昊鹏
郭小可
徐晓莉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Original Assignee
China Pharmaceutical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by China Pharmaceutical University filed Critical China Pharmaceutical University
Priority to CN201510648342.9A priority Critical patent/CN105130888A/zh
Priority to BR112018005969-2A priority patent/BR112018005969A2/pt
Priority to HUE15905721A priority patent/HUE049409T2/hu
Priority to LTEP15905721.5T priority patent/LT3360862T/lt
Priority to RU2018113258A priority patent/RU2692494C1/ru
Priority to KR1020187012413A priority patent/KR20180063229A/ko
Priority to PCT/CN2015/095728 priority patent/WO2017059623A1/zh
Priority to JP2018515119A priority patent/JP6635562B2/ja
Priority to PL15905721T priority patent/PL3360862T3/pl
Priority to EP15905721.5A priority patent/EP3360862B1/en
Priority to HK18107005.8A priority patent/HK1247613B/zh
Priority to HRP20200907TT priority patent/HRP20200907T1/hr
Priority to AU2015411258A priority patent/AU2015411258B2/en
Priority to UAA201804628A priority patent/UA120407C2/uk
Priority to CN201580079971.2A priority patent/CN107848976B/zh
Priority to MX2018003832A priority patent/MX379007B/es
Priority to ES15905721T priority patent/ES2794002T3/es
Priority to SI201531228T priority patent/SI3360862T1/sl
Priority to DK15905721.5T priority patent/DK3360862T3/da
Priority to US15/765,387 priority patent/US10889546B2/en
Priority to CA3000040A priority patent/CA3000040A1/en
Priority to PT159057215T priority patent/PT3360862T/pt
Publication of CN105130888A publication Critical patent/CN105130888A/zh
Priority to US17/018,221 priority patent/US20200407319A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201510648342.9A 2015-10-09 2015-10-09 炔基吡啶类脯氨酰羟化酶抑制剂、其制备方法和医药用途 Pending CN105130888A (zh)

Priority Applications (23)

Application Number Priority Date Filing Date Title
CN201510648342.9A CN105130888A (zh) 2015-10-09 2015-10-09 炔基吡啶类脯氨酰羟化酶抑制剂、其制备方法和医药用途
AU2015411258A AU2015411258B2 (en) 2015-10-09 2015-11-27 Alkynyl pyridine prolyl hydroxylase inhibitor, and preparation method and medical use thereof
HRP20200907TT HRP20200907T1 (hr) 2015-10-09 2015-11-27 Inhibitor alkinil piridin prolil hidroksilaze, metoda pripreme i njegova medicinska primjena
LTEP15905721.5T LT3360862T (lt) 2015-10-09 2015-11-27 Alkinilpiridinprolilhidroksilazės inhibitorius, ir jo gavimo būdas ir medicininis panaudojimas
RU2018113258A RU2692494C1 (ru) 2015-10-09 2015-11-27 Алкинилпиридиновый ингибитор пролилгидроксилазы, способ его получения и медицинское применение
KR1020187012413A KR20180063229A (ko) 2015-10-09 2015-11-27 알키닐 피리딘 프롤릴 하이드록실라제 저해제, 및 이의 제조 방법 및 의학적 용도
PCT/CN2015/095728 WO2017059623A1 (zh) 2015-10-09 2015-11-27 炔基吡啶类脯氨酰羟化酶抑制剂、其制备方法和医药用途
HUE15905721A HUE049409T2 (hu) 2015-10-09 2015-11-27 Alkinilpiridin-prolil-hidroxiláz inhibitor és annak elõállítási eljárása és gyógyászati alkalmazása
PL15905721T PL3360862T3 (pl) 2015-10-09 2015-11-27 Inhibitor hydroksylazy alkinylo-pirydyno-prolilowej oraz sposób jego wytwarzania i zastosowanie medyczne
EP15905721.5A EP3360862B1 (en) 2015-10-09 2015-11-27 Alkynyl pyridine prolyl hydroxylase inhibitor, and preparation method and medical use thereof
HK18107005.8A HK1247613B (zh) 2015-10-09 2015-11-27 炔基吡啶类脯氨酰羟化酶抑制剂、其制备方法和医药用途
BR112018005969-2A BR112018005969A2 (pt) 2015-10-09 2015-11-27 inibidor de alquinil piridina prolil hidroxilase e método de preparação e uso médico do mesmo
JP2018515119A JP6635562B2 (ja) 2015-10-09 2015-11-27 アルキニルピリジンプロリルヒドロキシラーゼ阻害剤、及びその製造法及び医薬用途
SI201531228T SI3360862T1 (sl) 2015-10-09 2015-11-27 Inhibitor alkinil-piridin-prolil-hidroksilaze in postopek priprave ter medicinska uporaba le-tega
CN201580079971.2A CN107848976B (zh) 2015-10-09 2015-11-27 炔基吡啶类脯氨酰羟化酶抑制剂、其制备方法和医药用途
MX2018003832A MX379007B (es) 2015-10-09 2015-11-27 Inhibidor de piridina alquinil prolil hidroxilasa, y metodo de preparacion y uso medico del mismo.
ES15905721T ES2794002T3 (es) 2015-10-09 2015-11-27 Inhibidor de alquinil piridina prolil hidroxilasa, y método de preparación y uso médico del mismo
UAA201804628A UA120407C2 (uk) 2015-10-09 2015-11-27 Інгібітор алкінілпіридинпролілгідроксилази та спосіб його отримання та застосування в медицині
DK15905721.5T DK3360862T3 (da) 2015-10-09 2015-11-27 Alkynylpyridinprolylhydroxylase-inhibitor samt forberedelsesfremgangsmåde og medicinsk brug deraf
US15/765,387 US10889546B2 (en) 2015-10-09 2015-11-27 Alkynyl pyridine prolyl hydroxylase inhibitor, and preparation method and medical use thereof
CA3000040A CA3000040A1 (en) 2015-10-09 2015-11-27 Alkynyl pyridine prolyl hydroxylase inhibitor, and preparation method and medical use thereof
PT159057215T PT3360862T (pt) 2015-10-09 2015-11-27 Inibidores alcinilpiridina da prolil-hidroxilase e método de preparação e utilização médica destes
US17/018,221 US20200407319A1 (en) 2015-10-09 2020-09-11 Alkynyl pyridine prolyl hydroxylase inhibitor, and preparation method and medical use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201510648342.9A CN105130888A (zh) 2015-10-09 2015-10-09 炔基吡啶类脯氨酰羟化酶抑制剂、其制备方法和医药用途

Publications (1)

Publication Number Publication Date
CN105130888A true CN105130888A (zh) 2015-12-09

Family

ID=54716523

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201510648342.9A Pending CN105130888A (zh) 2015-10-09 2015-10-09 炔基吡啶类脯氨酰羟化酶抑制剂、其制备方法和医药用途
CN201580079971.2A Active CN107848976B (zh) 2015-10-09 2015-11-27 炔基吡啶类脯氨酰羟化酶抑制剂、其制备方法和医药用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201580079971.2A Active CN107848976B (zh) 2015-10-09 2015-11-27 炔基吡啶类脯氨酰羟化酶抑制剂、其制备方法和医药用途

Country Status (20)

Country Link
US (2) US10889546B2 (https=)
EP (1) EP3360862B1 (https=)
JP (1) JP6635562B2 (https=)
KR (1) KR20180063229A (https=)
CN (2) CN105130888A (https=)
AU (1) AU2015411258B2 (https=)
BR (1) BR112018005969A2 (https=)
CA (1) CA3000040A1 (https=)
DK (1) DK3360862T3 (https=)
ES (1) ES2794002T3 (https=)
HR (1) HRP20200907T1 (https=)
HU (1) HUE049409T2 (https=)
LT (1) LT3360862T (https=)
MX (1) MX379007B (https=)
PL (1) PL3360862T3 (https=)
PT (1) PT3360862T (https=)
RU (1) RU2692494C1 (https=)
SI (1) SI3360862T1 (https=)
UA (1) UA120407C2 (https=)
WO (1) WO2017059623A1 (https=)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017059623A1 (zh) * 2015-10-09 2017-04-13 中国药科大学 炔基吡啶类脯氨酰羟化酶抑制剂、其制备方法和医药用途
CN107417605A (zh) * 2017-08-02 2017-12-01 江苏艾立康药业股份有限公司 作用于脯氨酰羟化酶的吡啶衍生化合物
CN109593084A (zh) * 2019-01-23 2019-04-09 中国药科大学 脯氨酰羟化酶小分子光敏前药及其制备方法与应用
WO2019080865A1 (zh) * 2017-10-25 2019-05-02 江苏恒瑞医药股份有限公司 一种炔基吡啶类脯氨酰羟化酶抑制剂的晶型及其制备方法
CN110240562A (zh) * 2018-03-08 2019-09-17 江苏恒瑞医药股份有限公司 一种脯氨酰羟化酶抑制剂的可药用盐、晶型及其制备方法
WO2019223764A1 (zh) 2018-05-24 2019-11-28 苏州盛迪亚生物医药有限公司 一种用于制备炔基吡啶类脯氨酰羟化酶抑制剂的方法
WO2020177681A1 (zh) * 2019-03-04 2020-09-10 江苏恒瑞医药股份有限公司 一种脯氨酰羟化酶抑制剂的药物组合物及其制备方法
CN112741834A (zh) * 2021-02-07 2021-05-04 复旦大学附属中山医院 HIF-1α降解抑制剂在制备酮体水平升高的冠心病药物中的应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116670131A (zh) * 2020-08-14 2023-08-29 阿克比治疗有限公司 Phd抑制剂化合物、组合物和使用方法
CN116120340B (zh) * 2021-11-15 2023-10-31 艾立康药业股份有限公司 一种吡啶并噁嗪类化合物及其制备方法、组合物和用途
CN116514710B (zh) * 2022-01-21 2024-07-05 中国药科大学 环取代炔基吡啶甲酰甘氨酸衍生物、制备方法、药物组合物和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101506149A (zh) * 2006-06-26 2009-08-12 宝洁公司 脯氨酰羟化酶抑制剂及使用方法
WO2012031298A2 (en) * 2010-09-03 2012-03-08 Duke University Ethynylbenzene derivatives
CN104024227A (zh) * 2011-07-22 2014-09-03 北京贝美拓新药研发有限公司 抑制脯氨酸羟化酶活性的化合物的晶型及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4410480A1 (de) * 1994-03-25 1995-09-28 Hoechst Ag Sulfonamidocarbonylpyridin-2-carbonsäureesteramide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
ES2393326T3 (es) * 2006-12-18 2012-12-20 Amgen, Inc Compuestos basados en azaquinolona que presentan actividad inhibidora de prolil hidroxilasas, composiciones y usos de los mismos
TW200845991A (en) * 2007-01-12 2008-12-01 Smithkline Beecham Corp N-substituted glycine derivatives: hydroxylase inhibitors
TW201141839A (en) * 2010-04-19 2011-12-01 Daiichi Sankyo Co Ltd Substituted 5-hydroxypyrimidine-4-carboxamide compounds
CN105130888A (zh) * 2015-10-09 2015-12-09 中国药科大学 炔基吡啶类脯氨酰羟化酶抑制剂、其制备方法和医药用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101506149A (zh) * 2006-06-26 2009-08-12 宝洁公司 脯氨酰羟化酶抑制剂及使用方法
WO2012031298A2 (en) * 2010-09-03 2012-03-08 Duke University Ethynylbenzene derivatives
CN104024227A (zh) * 2011-07-22 2014-09-03 北京贝美拓新药研发有限公司 抑制脯氨酸羟化酶活性的化合物的晶型及其应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MICHAEL H. RABINOWITZ: "Inhibition of Hypoxia-Inducible Factor Prolyl Hydroxylase Domain Oxygen Sensors: Tricking the Body into Mounting Orchestrated Survival and Repair Responses", 《JOURNAL OF MEDICINAL CHEMISTRY》 *

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017059623A1 (zh) * 2015-10-09 2017-04-13 中国药科大学 炔基吡啶类脯氨酰羟化酶抑制剂、其制备方法和医药用途
US10889546B2 (en) 2015-10-09 2021-01-12 Jiangsu Hengrui Medicine Co., Ltd. Alkynyl pyridine prolyl hydroxylase inhibitor, and preparation method and medical use thereof
CN107417605A (zh) * 2017-08-02 2017-12-01 江苏艾立康药业股份有限公司 作用于脯氨酰羟化酶的吡啶衍生化合物
JP2021500315A (ja) * 2017-10-25 2021-01-07 ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． アルキニルピリジンプロリル水酸化酵素阻害剤の結晶型及びその製造方法
CN111108098B (zh) * 2017-10-25 2022-06-21 江苏恒瑞医药股份有限公司 一种炔基吡啶类脯氨酰羟化酶抑制剂的晶型及其制备方法
WO2019080865A1 (zh) * 2017-10-25 2019-05-02 江苏恒瑞医药股份有限公司 一种炔基吡啶类脯氨酰羟化酶抑制剂的晶型及其制备方法
US11014888B2 (en) 2017-10-25 2021-05-25 Jiangsu Hengrui Medicine Co., Ltd. Crystalline form of alkynyl pyridine prolyl hydroxylase inhibitor and method for preparing same
CN111108098A (zh) * 2017-10-25 2020-05-05 江苏恒瑞医药股份有限公司 一种炔基吡啶类脯氨酰羟化酶抑制剂的晶型及其制备方法
CN110240562A (zh) * 2018-03-08 2019-09-17 江苏恒瑞医药股份有限公司 一种脯氨酰羟化酶抑制剂的可药用盐、晶型及其制备方法
CN110240562B (zh) * 2018-03-08 2022-04-12 江苏恒瑞医药股份有限公司 一种脯氨酰羟化酶抑制剂的可药用盐、晶型及其制备方法
CN111094246A (zh) * 2018-05-24 2020-05-01 苏州盛迪亚生物医药有限公司 一种用于制备炔基吡啶类脯氨酰羟化酶抑制剂的方法
WO2019223764A1 (zh) 2018-05-24 2019-11-28 苏州盛迪亚生物医药有限公司 一种用于制备炔基吡啶类脯氨酰羟化酶抑制剂的方法
CN111094246B (zh) * 2018-05-24 2023-03-10 苏州盛迪亚生物医药有限公司 一种用于制备炔基吡啶类脯氨酰羟化酶抑制剂的方法
CN109593084B (zh) * 2019-01-23 2021-09-28 中国药科大学 脯氨酰羟化酶小分子光敏前药及其制备方法与应用
CN109593084A (zh) * 2019-01-23 2019-04-09 中国药科大学 脯氨酰羟化酶小分子光敏前药及其制备方法与应用
WO2020177681A1 (zh) * 2019-03-04 2020-09-10 江苏恒瑞医药股份有限公司 一种脯氨酰羟化酶抑制剂的药物组合物及其制备方法
CN113056262A (zh) * 2019-03-04 2021-06-29 江苏恒瑞医药股份有限公司 一种脯氨酰羟化酶抑制剂的药物组合物及其制备方法
CN113056262B (zh) * 2019-03-04 2022-11-18 江苏恒瑞医药股份有限公司 一种脯氨酰羟化酶抑制剂的药物组合物及其制备方法
CN112741834A (zh) * 2021-02-07 2021-05-04 复旦大学附属中山医院 HIF-1α降解抑制剂在制备酮体水平升高的冠心病药物中的应用

Also Published As

Publication number Publication date
EP3360862B1 (en) 2020-04-22
KR20180063229A (ko) 2018-06-11
US20200407319A1 (en) 2020-12-31
HRP20200907T1 (hr) 2020-09-04
CN107848976B (zh) 2020-11-17
EP3360862A1 (en) 2018-08-15
CA3000040A1 (en) 2017-04-13
AU2015411258B2 (en) 2020-09-17
US10889546B2 (en) 2021-01-12
WO2017059623A1 (zh) 2017-04-13
AU2015411258A1 (en) 2018-05-10
RU2692494C1 (ru) 2019-06-25
ES2794002T3 (es) 2020-11-17
CN107848976A (zh) 2018-03-27
MX379007B (es) 2025-03-11
UA120407C2 (uk) 2019-11-25
PT3360862T (pt) 2020-05-27
BR112018005969A2 (pt) 2018-10-16
DK3360862T3 (da) 2020-06-02
SI3360862T1 (sl) 2020-08-31
JP2018529690A (ja) 2018-10-11
HUE049409T2 (hu) 2020-10-28
EP3360862A4 (en) 2018-08-15
US20180305317A1 (en) 2018-10-25
JP6635562B2 (ja) 2020-01-29
LT3360862T (lt) 2020-07-10
HK1247613A1 (zh) 2018-09-28
MX2018003832A (es) 2018-06-18
PL3360862T3 (pl) 2020-09-21

Similar Documents

Publication Publication Date Title
CN105130888A (zh) 炔基吡啶类脯氨酰羟化酶抑制剂、其制备方法和医药用途
CN104884447B (zh) 卤素取代杂环化合物
CN102766099B (zh) 具有黄嘌呤氧化酶抑制活性的化合物及其盐、制备方法和用途
EP3162801B1 (en) Salt of halogen-substituted heterocyclic compound
CN103304573B (zh) 石蒜碱类化合物在制备抗肿瘤药物的应用
CN107922374B (zh) 新型儿茶酚衍生物及含有它的药物组合物
JP7177577B2 (ja) 新規な化合物およびこれを含む薬学的組成物
AU2024204863A1 (en) Antiviral 1,3-di-oxo-indene compounds
HK1247613B (zh) 炔基吡啶类脯氨酰羟化酶抑制剂、其制备方法和医药用途
CN109293606B (zh) 2,5-双取代呋喃衍生物及其作为sirt蛋白抑制剂在药物制备中的用途
CN106496132B (zh) N-(4-取代苯基)-2-取代乙酰胺类化合物及其作为sirt2蛋白抑制剂的用途
RU2793138C2 (ru) Новые соединения и фармацевтический состав, содержащий их
CN101463019B (zh) 含有芳基、芳甲基和哌嗪基的脒类化合物
HK40088484A (zh) 抗病毒素1，3-二氧代茚化合物
WO2016107542A1 (zh) 吡咯酰胺类化合物及其制备方法与用途
HK40088065A (zh) 抗病毒素1，3-二氧代茚化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20170912

Address after: 222047 Kunlun Road, Lianyungang economic and Technological Development Zone, Jiangsu, No. 7

Applicant after: Hengrui Medicine Co., Ltd., Jiangsu Prov.

Address before: No. 639 road in Nanjing city in Jiangsu province 211198.

Applicant before: China Pharmaceutical University

TA01 Transfer of patent application right
AD01 Patent right deemed abandoned

Effective date of abandoning: 20180608

AD01 Patent right deemed abandoned